PMA/ionomycin stimulated NKT cells (as the ones profiled using human signatures in the anti-PD1 cohort of this study) previously presented to α-GalCer antigen through DCs-expressing CD1d, have been described to enhance the expression of IFN-γ, which ultimately impacts cancer immune microenvironment by increasing iNOS+CD206- M1 macrophage levels for melanoma control growth (59). The gene discussed is CD1D; the disease is cancer.